Online inquiry

IVTScrip™ mRNA-Anti-ERBB2, GEXMab73(Cap 1, 2-Thio-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ7706MR)

This product GTTS-WQ7706MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets ERBB2 gene. The antibody can be applied in Cancers research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_001005862.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2064
UniProt ID P04626
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-ERBB2, GEXMab73(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) (GTTS-WQ7706MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ10759MR IVTScrip™ mRNA-Anti-ADAMTSL5&ALB, M-6495(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA M-6495
GTTS-WQ7981MR IVTScrip™ mRNA-Anti-GHR, GX-H9(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA GX-H9
GTTS-WQ2697MR IVTScrip™ mRNA-Anti-SOST, AMG 785 (Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA AMG 785
GTTS-WQ15966MR IVTScrip™ mRNA-Anti-NGF, ZTS-00508841(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA ZTS-00508841
GTTS-WQ8210MR IVTScrip™ mRNA-Anti-SLC39A6, hLIV22(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA hLIV22
GTTS-WQ5730MR IVTScrip™ mRNA-Anti-CEACAM5, CEA-IL-2v(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA CEA-IL-2v
GTTS-WQ4556MR IVTScrip™ mRNA-Anti-CXCR4, BMS-936564(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA BMS-936564
GTTS-WQ13107MR IVTScrip™ mRNA-Anti-ACVRL1, PF-03446962(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA PF-03446962
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW